This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PDX1 | |
|---|---|
| Name | PDX1 |
| Uniprot | P06945 |
| Organism | Homo sapiens |
PDX1 PDX1 is a homeodomain transcription factor critical for pancreatic development, beta-cell specification, and maintenance of glucose-responsive insulin secretion. It was identified through studies in Mus musculus and Xenopus laevis embryology and is conserved across Mammalia and other Chordata. Mutations or altered regulation have been linked to congenital forms of diabetes and to dysfunctions observed in Type 2 diabetes mellitus, making it a focal point in studies from Harvard University to the Max Planck Society.
PDX1 encodes a 283–283 amino acid protein belonging to the homeobox family with roles delineated by developmental genetics studies in Danio rerio, Gallus gallus, and Drosophila melanogaster comparative analyses. Landmark discoveries involved collaborations among laboratories at Columbia University, University of California, San Francisco, and the National Institutes of Health, with findings published in journals such as Nature, Cell, and Science. Functional characterization has leveraged resources from the Jackson Laboratory and the European Molecular Biology Laboratory.
The PDX1 gene is located on human chromosome 13 and contains multiple exons identified in genomic mapping efforts by teams at Broad Institute and Wellcome Sanger Institute. The encoded protein includes an N-terminal transactivation domain, a central homeodomain responsible for DNA binding, and C-terminal regions mediating protein–protein interactions characterized by studies using techniques from Cold Spring Harbor Laboratory and EMBL-EBI. The homeodomain shows sequence conservation with other homeobox proteins studied at Stanford University and in phylogenetic surveys by Smithsonian Institution curators. Crystallographic and NMR structural work conducted at facilities such as European Synchrotron Radiation Facility and Brookhaven National Laboratory clarified the DNA-contacting residues and interface with cofactors from the Max Planck Institute for Biophysical Chemistry.
PDX1 expression is tightly regulated temporally and spatially during embryogenesis, first in the posterior foregut and later concentrated in pancreatic progenitors, as demonstrated by lineage-tracing studies from Yale University and inducible systems developed at MIT. Upstream regulators include signaling pathways such as Sonic Hedgehog, FGF10, Notch signaling pathway, and Wnt signaling pathway, with regulatory inputs mapped by consortia including ENCODE and laboratories at Karolinska Institutet. Epigenetic control involves histone modifications and DNA methylation observed in studies from University of Cambridge and University of Oxford, while post-translational modifications—phosphorylation by kinases characterized at Imperial College London and ubiquitination pathways studied at ETH Zurich—modulate stability and nuclear localization. Interaction partners include transcription factors documented in proteomic screens at European Molecular Biology Laboratory and coactivators studied at Salk Institute.
PDX1 is essential for specification of pancreatic bud identity in mammals and for differentiation of endocrine lineages, particularly insulin-producing beta cells, as shown in loss-of-function mouse models generated at the Howard Hughes Medical Institute and the Wellcome Trust. Functional assays in stem cell differentiation platforms at Stanford University and University of California, San Diego demonstrate that PDX1 cooperates with NEUROG3, NKX6-1, MAFA, and PAX6 to drive beta-cell maturation. In adult islets, PDX1 maintains beta-cell phenotype, regulates the insulin gene promoter, and influences glucose sensing via downstream targets studied in metabolic research centers such as Joslin Diabetes Center and Mayo Clinic. Cross-species transgenic experiments in Mus musculus and xenotransplantation studies coordinated by teams at University of Minnesota further delineate its functional repertoire.
Mutations in PDX1 underlie forms of monogenic diabetes, including early-onset syndromes identified in cohorts at Cedars-Sinai Medical Center and Mount Sinai Health System, and heterozygous variants contribute to susceptibility to Type 2 diabetes mellitus reported by international consortia including DIAGRAM and International HapMap Project analyses. Beta-cell dysfunction with reduced PDX1 expression is observed in human islet samples studied at University of Alberta and in clinical studies at M.D. Anderson Cancer Center where pancreatogenic diabetes and pancreatitis-associated endocrine failure have been profiled. Therapeutic strategies targeting PDX1 pathways are explored in regenerative medicine trials at University College London and biotech firms collaborating with Bill & Melinda Gates Foundation-funded initiatives, while gene-editing approaches using CRISPR-Cas9 are investigated in preclinical models at Broad Institute.
Experimental tools include PDX1-reporter mice, conditional knockouts produced at Jackson Laboratory, and human induced pluripotent stem cell lines engineered at Stanford University and Harvard Stem Cell Institute. High-throughput assays leveraging platforms from Illumina and single-cell transcriptomics carried out at Wellcome Sanger Institute have profiled PDX1-expressing populations. Protein–DNA interaction mapping using ChIP-seq and CUT&RUN protocols implemented at European Molecular Biology Laboratory and computational analyses by groups at Carnegie Mellon University have defined the PDX1 regulome. Organoid systems developed at Hubrecht Institute and xenograft models maintained at Fred Hutchinson Cancer Center provide functional contexts for testing modulators identified through chemical screens at EMBL.
Category:Transcription factors Category:Pancreatic development